Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM4003 in advanced solid tumors
NL-OMON50321Phase 1Withdrawn
- Sponsor
- Harbour BioMed
- Start
- Sep 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of porustobart in melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 1 more (4 arms), sponsored by Harbour BioMed. Primary endpoint: Objective response rate by RECIST 1.1. Planned start Sep 2021; status: withdrawn.
02
Drugs
porustobart
03
Conditions
melanomahepatocellular carcinoma (HCC)renal cell carcinoma (RCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON50321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50321.